Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL3193311 | 1.00 | LMNA (0.47) | LMNAMAPK1SRCCYP2D6MME | |
| Propylene Glycol SCHEMBL3192573 | 0.87 | LMNA (0.45) | LMNAMAPK1SRCCYP2D6MME | |
| Ethylene Glycol SCHEMBL3208351 | 0.86 | SRC (0.48) | LMNAMAPK1SRCCYP2D6MME | |
| Ethylene Glycol SCHEMBL5345328 | 0.86 | SRC (0.48) | LMNAMAPK1SRCCYP2D6MME | |
| SCHEMBL74366 | 0.85 | SRC (0.56) | LMNAMAPK1SRCCYP2D6MME | |
| Hydrochloric Acid SCHEMBL8340022 | 0.83 | SRC (0.54) | LMNAMAPK1SRCCYP2D6MME | |
| 1,3-Propanediol SCHEMBL5341712 | 0.82 | SRC (0.45) | LMNAMAPK1SRCCYP2D6MME | |
| SCHEMBL3202620 | 0.81 | SRC (0.43) | LMNAMAPK1SRCCYP2D6MME | |
| SCHEMBL3215199 | 0.81 | SRC (0.43) | LMNAMAPK1SRCCYP2D6MME | |
| Mandelic Acid SCHEMBL28226487 | 0.80 | LMNA (0.75) | LMNAMAPK1SRCCYP2D6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029876-A1 | POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND | SHOWA DENKO K.K. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2030989-A1 | POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING THIOL COMPOUND | Showa Denko K.K. (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029876-A1 | POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND | TMT1A, CCNT1, MGMT | LMNA 3457/4885MAPK1 2791/4885SRC 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.